Glick SD, Maisonneuve IM, Visker KE, Fritz KA, Bandarge UK, Kuehne MD,
18-METHOXYCORONARDINE ATTENUATES NICOTINE-INDUCED DOPAMINE RELEASE AND NICOTINE
PREFERENCE IN RATS, Psychopharmacology (1998) 139:274-280.

Abstract

"Two studies were conducted to assess, in vivo, potential anti-nicotine effects
of the iboga alkaloid ibogaine and its synthetic congener 18-methoxycoronardine
(18-MC).  As previously demonstrated for ibogaine, using microdialysis,
pretreatment (19 h beforehand) using 18-MC (40 mg/kg, IP) significanty
attenuated nicotine-induced dopamine release in the nucleaus accumbens of awake
and freely moving rats.  In an {*filter*}model of nicotine self-administration, both
ibogaine and 18-MC decreased rats' preferences for nicotine for at least 24 h.
Acutely, during the first hour after administration, ibogaine depressed
responding for water as well as for nicotine; however, during this same time,
18-MC reduced nicotine intake without affecting responding for water.  Thr
results suggest that 18-MC might be a prototype of a new treatment for
smoking."

The above research has demonstrated the effects predicted in early studies of
ibogaine stipulating that ibogaine was effective to treat a broad range fo
chemical dependencies including opioid narcotics, {*filter*} and amphetamine,
{*filter*}, nicotine and poly-drug dependence (H. Lotsof, U.S. patents numbers
4,449,096; 4,587,243; 4,857,523; 5,026,697; 5,124,994).  Research citations
include Glick et al. 1991 for decreased morphine self-administration; decreased
{*filter*} self-administration, Cappendijk and Dzoljic 1993; Glick et al. 1994;
decreased {*filter*} self-administration, Rezvani et at. 1995.  Ibogaine has
rarely been seen to interrupt the self-administration of {*filter*}.

For additional information http://www.***.com/